In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AZ pays $200mm up front for rights to Targacept's TC5214; deal terminated

Executive Summary

Building on what has proven to be a lucrative relationship over the past 4 years, CNS drug company Targacept has once again chosen AstraZeneca as a development partner. This time, Targacept has granted the Big Pharma exclusive worldwide rights to develop and sell its TC5214, a Phase II nicotinic channel blocker for major depressive disorder.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies